Shares of Lupin Ltd were trading in the green and almost 2% higher on 21 January after the company’s subsidiary, Lupin Atlantis Holdings SA, announced signing a licensing and supply agreement with Galenicum Health, S.L.U. 

The said agreement signed is for the finished formulations of injectable Semaglutide, a GLP-1 receptor agonist.

Under the agreement, Galenicum will lead the development, manufacturing, and supply of Semaglutide, while Lupin will handle regulatory filings, approvals, commercialization, and distribution across 23 countries. The markets include Canada, Europe, Southeast Asia, and Latin America. In its exchange filing, Lupin said the partnership positions the company to strengthen its leadership in diabetes and obesity care beyond India.

The collaboration with Galenicum enhances Lupin’s Semaglutide portfolio, as the drug emerges as a vital therapy amid the rising global burden of diabetes.

Fabrice Egros, President of Corporate Development at Lupin said, “With our extensive commercial presence across Canada, Europe, Southeast Asia, and Latin America we are positioned to scale access at the right moment – further reinforcing our commitment to delivering high-quality, cost-effective medicines and expanding access to Semaglutide for patients in these regions.”

Semaglutide is a glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar levels.

However, at 12:27 pm, the shares of Lupin were trading 0.45% lower at Rs 2,158.60 on NSE. 

The future of investing is here!
Tradz by EquityPandit leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app todayand 10x your trading & investing journey!